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ABSTRACT  
Acetylcholinesterase (AChE) is a key enzyme in the cholinergic nervous system, and is 
one of the most studied proteins in the field of Alzheimer's disease (AD). Moreover, 
alternative functions of AChE unrelated with the hydrolysis of acetylcholine are 
suspected. Until now, the majority of investigation on AChE in AD pathology has been 
focus in the determination of its enzymatic activity level, which is depleted in the AD 
brain.  Despite this overall decrease, AChE activity increases at the vicinity of the two 
hallmarks of AD, the amyloid plaques and the neurofibrillary tangles (NFT).  In fact, 
AChE may directly interact with Aβ in a manner that increases the deposition of Aβ to 
form plaques. In the context of protein-protein interactions, we have recently reported 
that AChE can interact with presenilin-1, the catalytic component of γ-secretase, 
influencing its expression level and also its activity. However, the alteration of AChE 
protein in AD brain has not been determined. Here, we demonstrated by Western 
blotting and immunohistochemistry that a prominent pool of enzymatically inactive 
AChE protein was existed in the AD brain. The potential significance of these 
unexpected levels of inactive AChE protein in the AD brain was discussed, especially in 
the context of protein-protein interactions with β-amyloid and presenilin-1.
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Introduction 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive 
loss of memory and cognition. Cholinergic depletion is a classical feature in the AD 
brain, associated with amyloid plaques and neurofibrillary tangles (NFT) (Davies and 
Maloney, 1976; Perry et al., 1977). A decrease in acetylcholinesterase (AChE), the 
enzyme that rapidly degrades the neurotransmitter acetylcholine at cholinergic 
synapses, has been reported in a large number of studies (for a review see García-
Ayllón et al., 2011). Nonetheless, because the substantial reduction in acetylcholine 
levels, a molecule with a critical role in cognitive function, the therapies designed to 
reverse the cholinergic deficit characteristics of AD are based on inhibitors of AChE 
(AChE-I) (Giacobini, 2003; Lleó et al., 2006). Furthermore, evidence indicates that 
cholinergic mechanisms can modulate amyloid metabolism (Nitsch et al., 1992; Rossner 
et al., 1998) and AChE-Is affect the amyloid expression (Mori et al., 1995; 
Zimmermann et al., 2005; Lahiri et al., 1997). Although, the therapeutic effect of 
present AChE-I drugs used in AD therapy is rather modest and has not met expectations 
(Small, 2005),  
The majority of investigation about AChE on AD progression and therapy has 
been based in the determination of its enzymatic activity level. However, AChE is much 
more than a cholinergic enzyme, and indeed other biological functions unrelated with 
its catalytic activity have been reported (Sternfeld et al., 1998; Dori et al., 2005; Grisaru 
et al., 2006). These alternative functions are probably related with the rich 
polymorphism of AChE that exists in different variants by alternative splicing, as well 
as the existence of different molecular forms (for a review see Massoulié, 2002). 
Moreover, AChE is present in non-cholinergic tissues and shares with several neural 
cell adhesion proteins high sequence similarity (Krejci et al., 1991). The presence of a 
Campanari et al. 4 
cholinesterase-like domain in those adhesion proteins may reflect the capacity of AChE 
in acting as protein-protein interactions. 
We have recently demonstrated an interaction between AChE and presenilin-1 
(PS1), the catalytic component of the γ-secretase complex (Silveyra et al., 2008; 2012a). 
γ-Secretase is a proteolytic enzymatic complex that participates in the processing of the 
amyloid precursor protein (APP), generating the β-amyloid peptide or Aβ (Kaether et 
al., 2006), the major constituent of the amyloid plaques (Masters et al., 1985; Kang et 
al., 1987).  Moreover, extensive studies by Inestrosa and co-workers showed that AChE 
directly interacted with Aβ (Alvarez et al., 1995; Inestrosa et al., 1996a; 1996b). Indeed, 
despite the overall decrease in the AD brain, AChE is increased at the vicinity of 
amyloid plaques and NFT (Ulrich et al., 1990; Gomez-Ramos et al., 1992; Wright et al., 
1993). The pathological implications of these and other AChE-amyloid 
interrelationships have remained elusive, but this is evident that AChE can influence 
amyloid processing and fibrillation via protein-protein interactions and not only through 
its cholinergic activity. Accordingly, new dual binding AChE-I, able to inhibit the 
AChE-induced Aβ aggregation, are in development (García-Palomero et al., 2008; 
Belluti et al., 2011; Viayna et al., 2013). In this context, recently has been demonstrated 
that a novel AChE-I, NP-9 (9-anthraldehyde pyrazoline derivative), which is able to 
interfere Aβ AChE interaction, attenuates Aβ aggregation and amyloid-induced toxicity 
in Alzheimer’s animal models (Mishra et al., 2013). 
Surprisingly, the vast majority of AChE studies in the AD brain, including 
histological studies, are focus on the AChE enzymatic level and not the protein level. 
Here, we present evidence that, in the AD brain, the level of AChE protein does not 
accord with the decrease in enzymatic activity level. We also discuss the potential 
physiopathological consequences of the presence of this unexpected large pool of non-
enzymatically active AChE in the pathological brain.  
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Material and methods  
Collection of human brain samples 
This study was approved by the ethics committee of the Miguel Hernandez University, 
and was carried out in accordance with the Declaration of Helsinki. Frozen brain 
samples [five AD cases, aged 78-91 years (mean 83 years), and five control cases; aged 
60-73 years (mean 66 years)] were obtained from the UIPA neurological tissue bank 
(Unidad de Investigación Proyecto Alzheimer; Madrid, Spain). Fixed human brain 
tissues [four AD cases, aged 75-82 years (mean 80), and one control cases; aged 69 
years] were obtained from the UIPA neurological tissue bank, the Instituto de 
Neuropatología (IDIBELL-Hospital Universitario de Bellvitge, Barcelona, Spain) and 
from the Servicio de Patología Forense (Instituto Vasco de Medicina Legal, Bilbao, 
Spain). After neuropathological examination, sporadic AD cases were categorized as 
stages V-VI of Braak and Braak (Braak and Braak, 1991). Samples from non-disease 
individuals correspond to cases with no clinical dementia and no evidence of brain 
pathology. The mean postmortem interval of the tissue was between 1.5 and 6 h, with 
no significant difference between each group of samples. 
 
Preparation of human brain samples for biochemical analysis  
Samples (~0.1 g) of human frontal cortex, stored at -80 ºC, were thawed slowly at 4ºC 
and homogenized (10% v/v) in 50 mM Tris-HCl, pH 7.5 / 150 mM NaCl / 5 mM EDTA 
/ 1% (w/v) Nonidet P-40 / 0.5% (w/v) Triton X-100 and supplemented with a cocktail 
of protease inhibitors (Sáez-Valero et al., 1993). The homogenates were sonicated and 
centrifuged at 70000×g at 4 ºC for 1h, and the supernatants were collected and frozen at 
-80 ºC until assay. 
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AChE enzymatic assay and protein determination 
A modified microassay version of the colorimetric Ellman’s method was used to 
measure AChE (Sáez-Valero et al., 1993), using 50 μM tetraisopropyl 
pyrophosphoramide (iso-OMPA) as specific inhibitor for the structurally related 
butyrylcholinesterase, an enzyme that coexists with AChE in the human brain. One 
milliunit (mU) of AChE activity was defined as the number of nmoles of 
acetylthiocholine hydrolyzed per minute at 22 ºC. Total protein concentrations were 
determined using the bicinchoninic acid method (Pierce). AChE specific activity is 
expressed as the activity of the enzyme in mU per milligram (mg) of total protein 
(mU/mg). 
 
Western blotting assays 
Fifty micrograms of protein from brain extracts (equal amount of protein in each lane) 
were separated by SDS-PAGE electrophoresis. Samples were denatured at 98 ºC for 7 
min. The separated proteins were transferred to nitrocellulose membranes (Schleicher & 
Schuell Bioscience GmbH) and probed with the goat anti-AChE antibody N19 (Santa 
Cruz Biotech) and rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
(Abcam). The blots were incubated with the corresponding secondary antibody 
conjugated to horseradish peroxidase and the signal was detected using ECL Plus 
detection reagent according to the manufacturer’s instructions (GE Healthcare) in a 
Luminescent Image Analyzer LAS-1000 Plus (FUJIFILM). For semi-quantitative 
analysis, protein levels were normalized to GAPDH, and the intensity of bands was 
measured by densitometry with the Science Lab Image Gauge v4.0 software provided 
by FUJIFILM. 
 
Preparation of human brain samples for immunohistochemistry and histochemistry 
Campanari et al. 7 
Upon removal, the brain tissue was immediately fixed in cold 4% paraformaldehyde in 
phosphate buffer (PB: 0.1 M, pH 7.4), and after 2 h, the tissue was cut into small blocks 
and post-fixed in the same fixative for 24–48 h at 4 ºC. After fixation, all the specimens 
were immersed in graded sucrose solutions, and they were stored in a cryoprotectant 
solution at −20 ºC. Serial vibratome sections (50 µm) of cortical tissue were obtained, 
and the sections from each region and case were batch-processed for 
immunocytochemical staining. The sections immediately adjacent to those stained 
immunocytochemically were Nissl-stained as to identify the cortical areas to which they 
pertained and the laminar boundaries. Same AD and ND case were extensive studied by 
scores for the amyloid and neurofibrillary pathologies, as in a previous study (Blazquez-
Llorca et al., 2011). 
 
Immunohistochemistry and staining procedure 
Free-floating hippocampal sections were pre-treated in 1% H2O2 for 30 min to remove 
endogenous peroxidase activity, and subsequently they were blocked for 1 h in 
phosphate buffer (PB) with 0.25% Triton-X and 3% normal rabbit serum (1:200, Vector 
Laboratories Inc.). The sections were incubated overnight at 4 ºC with the N19 (1:500) 
antibody and the following day, the sections were rinsed and incubated for 2 h with 
biotinylated rabbit anti-goat IgG (1:200, BA-5000, Vector Laboratories). The sections 
were then incubated for 1 h in an avidin–biotin peroxidase complex (Vectastain ABC 
Elite PK6100, Vector), and finally with the 3,3′-diaminobenzidine tetrahydrochloride 
chromogen (DAB, Sigma-Aldrich). After staining, the sections were dehydrated, 
cleared with xylene and coverslipped. Control sections were processed as above but 
without the primary antibodies, and no significant staining was seen under these 
conditions.  
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 The AChE enzymatic reaction was performed according to the method of 
Karnovsky and Roots (Karnovsky and Roots, 1964). Slices were incubated for 2h in the 
medium containing: acetylthiocholine iodide (0.05%), 5 mM K3Fe(CN)4 (0.164%), 30 
mM CuSO4 (0.75%), and 0.1 mM sodium citrate (2.94%) in 0.2 M acetate buffer (pH 
6.0) (1.64%). The reaction was stopped with washes in phosphate-buffered saline. Then, 
the sections were dehydrated, cleared with xylene and coverslipped. 
 
Statistical analysis 
All data were analyzed using SigmaStat (Version 2.0; SPSS Inc.) by Student’s t-test 
(two tailed). Results are presented as means ± SEM. p values < 0.05 were considered 
significant.
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Results  
The level of AChE in frontal cortex extracts from AD and ND subjects were screened 
for enzymatic activity. As expected, the AChE assay revealed that AD samples had 
lower enzymatic activity (40% decrease; p= 0.003), in comparison to age and gender-
matched ND controls (Fig. 1A).  
Sample aliquots were analyzed by SDS-PAGE under fully reducing conditions, 
followed by Western blotting using anti-AChE antibody N19, raised against a peptide 
that maps the N-terminus of human AChE, common to all variants. N19 detected  AChE 
bands of ~75 and ~65 kDa, and a doublet of bands at ~55 and ~50 kDa in brain samples 
from both AD and non-disease (ND) control subjects (Fig. 1B). Although the predicted 
molecular weight of the AChE subunits is ~70 kDa in size, our as well as other studies 
strongly suggest the identity of lower AChE molecular weight bands (García-Ayllón et 
al., 2006; 2007; 2010; 2012; Santos et al., 2007; Sternfeld et al., 2000; Xie et al., 2011). 
The lower molecular weight bands might originate by post-translation modification 
and/or resulted from the reducing conditions used during electrophoresis.  We have 
previously confirmed the specificity of the AChE bands, including the lighter subunits, 
by AChE immunoprecipitation and probing blots with alternative anti-human AChE 
antibodies (García-Ayllón et al., 2007; 2010). Interestingly, the decrease in AChE 
enzyme activity was not paralleled by changes in AChE protein immunoreactivity. The 
levels of immunoreactive AChE bands were not significantly different in AD samples in 
comparison with ND controls (Fig. 1B).  
Immunohistochemical examination of AD brain yielded similar results (Fig. 2).  
The AChE protein staining pattern was studied in hippocampus from 3 AD patients and 
one ND control case. Sections from AD and control brain showed similar 
immunoreactivity to the anti-AChE antibody N19. Moreover, AChE-positive fibers 
stained with the N19 antibody seemed to be denser around amyloid plaques in AD 
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patients (Fig. 2B), when compared with other regions far from plaque or the control 
case. Similarly to previous reports (Ulrich et al., 1990; Gomez-Ramos et al., 1992; 
Wright et al., 1993), when the AChE enzymatic reaction was performed by the 
Karnovsky and Roots method (Karnovsky and Roots, 1964), no fibers were observed, 
but the amyloid plaques and NFT were stained (Fig. 2B, inset). 
Campanari et al. 11 
Discussion 
Here we report that AChE protein level appears unexpectedly preserved in the AD 
brain, respect to the decline in activity level. Frontal cortex samples, assayed by 
immunoblotting, and hippocampus sections, resolved by immunohistochemistry, 
demonstrate that AChE protein levels are comparable between AD and ND subjects. 
Despite the limitation of the low number of samples analyzed, our data signify 
discrepancies between the levels of AChE activity and AChE protein immunoreactivity, 
which may be attributable in part to the inactive or subnormal active character of AChE 
subunits present in the pathological tissues. Moreover, AChE banding pattern obtaining 
by electrophoretic analysis/Western blotting has no simple relationship to specific 
molecular forms or enzymatic activity (García-Ayllón et al., 2006; 2007). For this 
reason, the detriment in the major tetrameric form of AChE is not patent in 
immunoreactivity changes of particular bands. Further analyses with antibodies for 
specific variants are pending. 
There is extensive number of investigations in effort to identify alterations in 
AChE level as a consequence of AD processes. Most of them based on biochemical 
determination of enzymatic activity, probably because the facility in measuring the 
activity of the enzyme, and also because the interest derived from the use of AChE-I in 
therapy. Today it is well established that substantial loss of AChE activity is due to loss 
of a tetrameric form linked to the plasma membrane (Atack et al., 1983; Sáez-Valero et 
al., 1999). Enzymatic histochemical examination of AD brain yielded similar results 
than biochemical determination with an overall depletion of AChE activity (Ulrich et 
al., 1990; Gomez-Ramos et al., 1992; Wright et al., 1993). In vivo studies by positron 
emission tomography, based in the assessment of enzymatic activity using radiolabeled 
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analogues of acetylcholine, also suggested that AChE activity could be reduced in the 
AD brain (Iyo et al., 1997; Herholz, 2008; Mori et al., 2012). 
Several laboratories attempted to develop and enzyme-linked immunosorbent 
assay (ELISA) for AChE (Rasmussen et al., 1989; Blennow et al., 2007; Darreh-Shori 
et al., 2008), but very few develop a two-site immunoassay (Brimijoin et al., 1987; 
Weikert et al., 1994; Konings et al., 1995). Hammond and Brimijoin (1998) reported a 
parallel variation in AChE enzyme activity and AChE immunoreactivity, assessed by a 
two-site ELISA in the AD brain, but this ELISA probably assessed only protein levels 
for the major tetrameric form. Previously, we had noted that a large amount of AChE 
subunits found in AD samples, and identified by Western blotting with several 
polyclonal anti-AChE antibodies, displayed low affinity for certain monoclonal 
antibodies, which recognized native AChE (Sáez-Valero et al., 2000; García-Ayllón et 
al., 2007; 2010). As commented above, the lack of correlation between catalytic activity 
and immunostaining may be attributable, at least in part, to the presence of large amount 
of inactive AChE subunits. 
The existence of inactive AChE has been demonstrated in brain (Chatel et al., 
1993). These inactive AChE species are probably monomers, which could serve a 
reservoir for the active enzyme (Stieger, et al., 1987; Rotundo, 1988). Anyhow, the 
presence of large amount of inactive monomers in fluids, such as cerebrospinal fluid 
(CSF) and plasma (Darreh-Shori et al., 2004; García-Ayllón et al., 2007; 2010), 
suggests that these light species might have more than a simple role as precursors of 
enzymatically active oligomers. Despite several evidences strongly supports the 
possibility that AChE can act independently of acetylcholine hydrolysis, the 
physiological significance of the non-enzymatic AChE in the brain still is controversial, 
as catalytic and non-catalytic effects cannot be easily distinguished (reviewed in 
Massoulié et al., 1993; Balasubramanian and Bhanumathy, 1993; Small et al., 1996; 
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Layer, 1995; Soreq and Seidman, 2001; Greenfield et al., 2008). Indeed, transgenic 
over-expression of enzymatically inactivate AChE (Sternfeld et al., 1998; Dori et al., 
2005; Grisaru et al., 2006) or heat-inactivated AChE (Klegeris et al., 1994) have 
demonstrated to exert distinct biological functions. Possible biological functions for the 
pool of AChE non-enzymatically active in the normal brain, and particularly in the AD 
brain, therefore need to be elucidated. 
The occurrence of AChE subnormal active in the pathological tissue cannot be 
discarded. In this context, AChE activity present in the AD brain associated with 
plaques and NFT display particular enzymatic properties and sensitivity to inhibitors 
(Geula and Mesulam, 1989; Wright et al., 1993). However, it is not clear whether the 
atypical histochemical behavior of AChE observed in AD is due to alterations in kinetic 
properties of these enzymes (Ciro et al., 2012), or  due to interactions with other 
molecules within these lesions (Darvesh et al., 2010). In the context of the presence of 
AChE within plaques and NFT, it is important to note that both AD effectors, Aβ and 
abnormally hyperphosphorylated tau, can influence AChE levels in vitro (Sberna et al., 
1997; Sáez-Valero et al., 2003; Hu et al., 2003; Melo et al., 2003) and in rodent models 
(Sberna et al., 1998; Sáez-Valero et al., 2002; Silveyra et al., 2012b; Kreutz et al., 
2013). We have also demonstrated that Aβ alters AChE glycosylation in vivo (Sberna et 
al., 1998; Fodero et al., 2002), and this change is similar to the change in the 
glycosylation pattern of AChE in AD brain (Sáez-Valero 1997; 1999; 2000). Correct 
glycosylation determines the adequate biological function by influencing trafficking, 
folding, assembly and final localization of glycoproteins. Changes in glycosylation 
could compromises enzymatic capacities. The glycosylation pattern of the inactive 
AChE pool in the Alzheimer’s condition has not been studied. 
Non-catalytic AChE is not the unique AChE pool that remains unaltered, or 
even increase, in the AD brain. The significance of different variants and forms of 
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AChE is intriguing, as their specific subcellular distribution is thought to reflect specific 
physiological functions. Despite the loss of the major tetrameric and cholinergic AChE, 
the minor monomeric form increases in respect to the normal levels in non-pathological 
brain (Atack et al., 1983; Arendt et al., 1992; Sáez-Valero et al., 1999). So far, the 
significance of an increase in minor AChE species is controversial, as the relative 
increase is compared in absolute terms with the major cholinergic form. However, a 
variation in a particular AChE forms (with little impact on cholinergic equilibrium) 
could have impact at functional level with biological consequences, since particular 
forms or variants may have specific functions. Indeed, recent evidences indicate  
distinct, and in certain cases inverse cell fate outcome under enforced expression of the 
human N- and C-terminally modified AChE variants, all of which have similar 
enzymatic activities (Berson et al., 2008; Toiber et al., 2008; Greenberg et al., 2010). 
Brain AChE splice variants show indistinguishable enzymatic activity, but may present 
particular banding pattern by Western blotting (Meshorer and Soreq H, 2006). 
Additional studies regarding the specific roles of particular AChE species is mandatory 
in other to develop more effective therapies. In this regard, targeting a specific AChE 
variant (e.g. by antisense or siRNA agents) could hence offer specific advantages. 
Indeed, the AChE-targeted microRNA-132 has been recently reported to be down-
regulated during the progression of AD (Lau et al., 2013); and the possibility to 
intercept microRNA-132-mediated damages by modulating AChE expression has been 
demonstrated viable (Shaltiel et al., 2013). 
The interaction of AChE with the catalytic subunit of the γ-secretase complex, 
PS1, it is also of interest. We have demonstrated the reciprocal co-immunoprecipitation 
of AChE with PS1 (Silveyra et al., 2008), and the modulation of PS1 levels by AChE-I 
(Silveyra et al., 2012a). More interestingly, we have recently seen changes in PS1 levels 
under the influence of AChE genetic expression (Silveyra et al., 2012a), even using of 
Campanari et al. 15 
inactive catalytic mutants of the enzyme (unpublished). The modulatory effect on PS1 
levels was not sustained when AChE-I promotes feed-back AChE up-regulation 
(Silveyra et al., 2012b). All together these results suggest that excess of inactive or 
inactivated brain AChE can exert a variety of unpredictable effects, and maybe induce 
vulnerability in the pathological brain. 
In conclusion, a better understanding of the alternative functions of AChE and 
estimation of its protein levels could be relevant for deciphering their implication in the 
progression of Alzheimer’s pathology and development of new therapy.
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FIGURE LEGENDS 
 
Figure 1. Decrease in AChE activity does not parallel changes in AChE protein in 
the Alzheimer’s brain. (A) AChE activity levels in frontal cortex extracts from non-
demented (ND) controls (n= 5) and patients with Alzheimer’s disease (AD) (n= 5). (B) 
Aliquots of the same brain extracts were immunoblotted with the anti-AChE antibody 
N19, which recognizes all variants. Representative immunoblot (left panel) and 
densitometric quantification (right panel) of the AChE-immunoreactive bands, 
expressed in arbitrary units (a u.), are shown. For the semiquantitative analysis, protein 
levels were normalized to GAPDH. The results were confirmed in two independent 
determinations with equivalent amounts of protein loaded in each lane. Columns 
represent means ± SEM.  *Significantly different (p < 0.05) from the ND group. 
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Figure 2. Immunohistochemical detection of AChE in human hippocampus. 
Immunostaining with the anti-AChE antibody N19, in the subiculum from a control 
case (A), and an AD patient (B). Inset in B correspond to AChE enzymatic reaction in 
the subiculum from the same AD subject. AChE-positive fibers stained with the N19 
antibody seem to be denser around amyloid plaques (surrounded by arrow heads). When 
the AChE enzymatic reaction was performed no fibers were observed but the amyloid 
plaques and NFT (inset in B) were stained. Scale bar: 35µm in A, B; 80µm in inset in B. 
